When cells survive, health therapies come into focus

Millions of people suffer from dry eyes and blindness. Think about how often we take our sight for granted until we or someone we know are affected by conditions like diabetes and macular degeneration. Researchers believe AAGP® could lead to a future where some causes of blindness could be overcome.

The impact of AAGP®

According to Centers for Disease Control and Prevention, as many as 12 million Americans live with vision impairment. By regenerating retinal cells in humans, AAGP® has the potential to treat people suffering from eye conditions.

We’re researching three major ways that AAGP® can help: retinal cell transplantation, ocular inflammation and veterinary treatments.

Applications of AAGP® in Ophthalmology

According to the Mayo Clinic, dry eye disease occurs when our bodies cannot produce enough tears to adequately lubricate our eyes. This can result in discomfort, itching, stinging, burning and even vision problems.

Person having eye exam

In addition to other complications, diabetes can adversely affect the eyes by causing diabetic retinopathy, or damage and deterioration of the blood vessels in the retina. In fact, diabetic retinopathy is the number one cause of blindness in young adults, according to the American Academy of Family Physicians. 

Physician inspecting patient's eye

According to the National Eye Institute, age-related macular degeneration (AMD) is a disease often occurring in older people, involving damage to the macula (the focal center of the eye responsible for “20/20” color vision), which can affect the central vision required for daily activities, such as reading, cooking and driving.

Senior putting eye drops in

Sjogren’s syndrome is an autoimmune condition in which a body’s own immune system attacks the cells in the moisture-producing salivary glands and tear ducts. The outcome of this autoimmune response is painfully dry eyes and mouth.

Clear eye comparison with inflamed eye

Uveitis is an inflammation of the uvea, or eye wall—the middle layer of tissue of the eye. Whereas conjunctivitis affects the outer layer of the eye, uveitis affects the interior of the eye in the front, middle, or back of the organ.

Research Pipeline for Ophthalmology:



We are in stage-3 of our pre-clinical retinal replacement program. The Gregory-Evans Retinal Therapeutic Lab at The University of British Columbia is testing whether AAGP® treated cells continue to develop into retinal cells. If successful, this could lead to the restoration of vision in humans. For example, retinal cell replacement therapy could become a critical approach for the treatment of retinal diseases including Age-Related Macular Degeneration (AMD).



Dry eye disease afflicts more than 30 million people in America and 430 million people around the world. We’re going to look into the effects of AAGP® on ocular inflammation when applied topically. With this biotechnology, we’re hoping to improve the quality of tears that lubricate and nourish the eye. This will help the hundreds of millions of people affected by this chronic issue.

Veterinary treatments



It’s possible that you don’t suffer from dry eye or other eye conditions, but your pets do. We plan on researching AAGP® in veterinary treatments. As we move through the discovery phase, we’ll narrow down our line of exploration to find out how we can improve ophthalmology care in animals.

Explore other Industry applications for AAGP®

For investors

At ProtoKinetix, we calculate the market value of AAGP® in how well it can take care of patients. We want to help medical treatments become more successful in improving lives and helping cells survive. But we know that as an investor, you also want to know how our biotechnology can help you.

The 2025 market forecast for the ophthalmology industry is $35.7 billion. Investing in the future of ophthalmology medicine will help you and the tens of millions of people in America who are living with vision impairment. The potential of our anti-aging glycopeptide is endless, and we’ve only seen the tip of the iceberg.

Invest with us

ProtoKinetix has patented an anti-aging glycopeptide with the power to change lives through cell survival. The potential is endless, and we’ve only seen the tip of the iceberg. Get invested.

Find answers in our investor FAQ

Find answers to our most commonly asked questions or submit your own.

Press releases

We’re already making headlines with our groundbreaking research on the impact AAGP® could have in the field of ophthalmology.

Connect With Protokinetix
Contact the team at ProtoKinetix to learn more about AAGP®’s potential for ophthalmology applications.